Petersenn S - Search Results

1

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.

Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A. Petersenn S, et al. J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24. J Clin Pharmacol. 2014. PMID: 24800725 Clinical Trial.

2

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J. Boscaro M, et al. Among authors: petersenn s. J Clin Endocrinol Metab. 2009 Jan;94(1):115-22. doi: 10.1210/jc.2008-1008. Epub 2008 Oct 28. J Clin Endocrinol Metab. 2009. PMID: 18957506 Clinical Trial.

3

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM; Pasireotide Acromegaly Study Group. Petersenn S, et al. J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9. doi: 10.1210/jc.2009-2272. Epub 2010 Apr 21. J Clin Endocrinol Metab. 2010. PMID: 20410233 Clinical Trial.

4

Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.

Schopohl J, Strasburger CJ, Caird D, Badenhoop K, Beuschlein F, Droste M, Plöckinger U, Petersenn S; German Lanreotide Study Group. Schopohl J, et al. Among authors: petersenn s. Exp Clin Endocrinol Diabetes. 2011 Mar;119(3):156-62. doi: 10.1055/s-0030-1267244. Epub 2010 Nov 17. Exp Clin Endocrinol Diabetes. 2011. PMID: 21086246 Clinical Trial.

5

Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.

Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K. Petersenn S, et al. J Clin Pharmacol. 2012 Jul;52(7):1017-27. doi: 10.1177/0091270011408727. Epub 2011 Jun 14. J Clin Pharmacol. 2012. PMID: 21673137 Clinical Trial.

6

Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.

Petersenn S, Hu K, Maldonado M, Zhang Y, Lasher J, Bouillaud E, Wang Y, Mann K, Unger N. Petersenn S, et al. Clin Ther. 2012 Mar;34(3):677-88. doi: 10.1016/j.clinthera.2012.01.015. Epub 2012 Feb 24. Clin Ther. 2012. PMID: 22364824 Clinical Trial.

7

Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.

Manolopoulou J, Alami Y, Petersenn S, Schopohl J, Wu Z, Strasburger CJ, Bidlingmaier M. Manolopoulou J, et al. Among authors: petersenn s. Clin Chem. 2012 Oct;58(10):1446-56. doi: 10.1373/clinchem.2012.188128. Epub 2012 Aug 20. Clin Chem. 2012. PMID: 22908135

8

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.

Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M, Hermosillo Reséndiz K, Hughes G, Hu K, Barkan A. Petersenn S, et al. Pituitary. 2014 Apr;17(2):132-40. doi: 10.1007/s11102-013-0478-0. Pituitary. 2014. PMID: 23529827 Free PMC article. Clinical Trial.

9

High variability in baseline urinary free cortisol values in patients with Cushing's disease.

Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BM; Pasireotide B2305 Study Group. Petersenn S, et al. Clin Endocrinol (Oxf). 2014 Feb;80(2):261-9. doi: 10.1111/cen.12259. Epub 2013 Jul 15. Clin Endocrinol (Oxf). 2014. PMID: 23746264 Free PMC article. Clinical Trial.

10

Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.

Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, Schopohl J, Snyder P, Hughes G, Trovato A, Hu K, Maldonado M, Biller BM. Boscaro M, et al. Among authors: petersenn s. Pituitary. 2014 Aug;17(4):320-6. doi: 10.1007/s11102-013-0503-3. Pituitary. 2014. PMID: 23943009 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

183 results

Search Page